ABCL(AbCellera Biologics Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $375.20M | $485.42M | $38.02M | $28.83M | $75.13M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | $204.41M | $216.51M | −$237.21M | −$314.77M | −$217.10M |
| 净利润 | $153.46M | $158.52M | −$146.40M | −$162.86M | −$146.41M |
| 经营现金流 | $244.58M | $277.36M | −$43.88M | −$108.56M | −$131.29M |
| 自由现金流 | $186.13M | $206.70M | −$120.82M | −$186.95M | −$174.07M |
| 摊薄每股收益 | $0.48 | $0.50 | $-0.51 | $-0.55 | $-0.49 |